Finally, we retrospectively investigated the correlation between the expression of the mesenchymal-related protein vimentin and the clinical efficacy of alectinib in 34 treatment-naïve patients with ALK-rearranged NSCLC. Here, VIM is linked to non-small cell lung carcinoma.